Effect of anlotinib in advanced small cell lung cancer (SCLC) patients relapsed within three months after second-line treatment: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202).
DOI: 10.1200/jco.2020.38.15_suppl.9063
文献链接: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.9063
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Jianhua Shi; Ying Cheng; Qiming Wang; Kai Li; Lin Wu; Baohui Han; Gongyan Chen; Jianxing He; Jie Wang; Haifeng Qin; Xiao-Ling Li

